Comparative study using indocyanine green and patent blue dye for sentinel lymph node biopsy in patients with early-stage cervical cancer
View abstract on PubMed
Summary
This summary is machine-generated.Indocyanine green offers superior sentinel lymph node detection in early cervical cancer compared to patent blue. Combining both tracers further enhances detection rates for accurate staging.
Area Of Science
- Gynecologic Oncology
- Surgical Pathology
- Medical Imaging
Background
- Lymphatic involvement is a critical prognostic factor in early-stage cervical cancer.
- Sentinel lymph node biopsy (SLNB) is an alternative to lymphadenectomy for precise metastasis identification.
Purpose Of The Study
- To compare the efficacy of indocyanine green (ICG) and patent blue (PB) tracers in detecting sentinel lymph nodes (SLNs) for early-stage cervical cancer.
- To evaluate the combined use of both tracers and their impact on detection rates and accuracy.
Main Methods
- Retrospective analysis of 103 patients with early-stage cervical cancer (FIGO 2009 IA1-IB1).
- SLNs were detected using ICG and/or PB and analyzed via frozen section and ultrastaging.
- Comparison of bilateral detection rates, tracer performance, and accuracy of frozen section analysis.
Main Results
- Indocyanine green demonstrated a significantly higher bilateral detection rate (93.2%) than patent blue (77.7%).
- Combined use of ICG and PB achieved a 99.0% bilateral detection rate.
- Nine positive nodes were detected; ICG identified all positive nodes, while PB identified six. Frozen section had limited sensitivity (43%) for detecting micrometastases.
Conclusions
- Indocyanine green offers superior bilateral detection and sensitivity for identifying positive sentinel nodes in early cervical cancer compared to patent blue.
- Combining indocyanine green and patent blue significantly improves sentinel lymph node detection rates.
- Ultrastaging remains crucial for accurate assessment of micrometastases missed by frozen section.

